Antithrombotic therapy and bleeding risk in atrial fibrillation. Fewer unanswered questions

 

Editorial Focus on: Azoulay et al. Thromb Haemost 2013; 109: 431-439.

• References

• 1 Camm AJ, Lip GY, De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
• 2 Lip GY, Nieuwlaat R, Pisters R. et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010; 137: 263-272.
• 3 Keogh C, Wallace E, Dillon C. et al. Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Throm Haemost 2011; 106: 528-538.
• 4 Olesen JB, Torp-Pedersen C, Hansen ML. et al. The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study. Throm Haemost 2012; 107: 1172-1179.
• 5 Friberg L RM, Lip GYH. Net clinical benefit of warfarin in patients with atrial fibrillation. Circulation 2012; 125: 2298-2307.
• 6 Olesen JB, Lip GYH, Lindhardsen J. et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study. Thromb Haemost 2011; 106: 739-749.
• 7 Rodríguez-Maáero M, Cordero A, Bertomeu-González V. et al. Impacto de los nuevos criterios para el tratamiento anticoagulante de la fibrilación auricular. Rev Esp Cardiol 2011; 64: 649-653.
• 8 Hart RG, Boop BS, Anderson DC. Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995; 26: 1471-1477.
• 9 Hart RG, Diener HC, Yang S. et al. Intracranial hemorrhage in atrial fibrillation during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke 2012; 46: 1511-1517.
• 10 Connolly SJ, Pogue J, Hart RG. et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. ACTIVE Investigators, N Engl J Med 2009; 360: 2066-2078.
• 11 Lip GY, Andreotti F, Fauchier L. et al. Bleeding risk assessment and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association [EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost 2011; 106: 997-1011.
• 12 Pisters R, Lane DA, Nieuwlaat R. et al. A Novel User-Friendly Score (HAS-BLED) to assess one-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138: 1093-1100.
• 13 Gallego P, Roldán V, Torregrosa JM. et al. Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events and mortality in patients with atrial fibrillation. Circ Arrhythm Electrophysiol 2012; 5: 312-318.
• 14 Ruiz-Nodar JM, Marín F, Roldán V. et al. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?. Circ Cardiovasc Interv 2012; 5: 459-466.
• 15 Azoulay L, Dell’Aniello S, Simon T. et al. The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation. Thromb Haemost 2013; 109: 431-439.
• 16 Lip GY, Huber K, Andreotti F. et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting. Thromb Haemost 2010; 103: 13-28.
• 17 Faxon DP, Eikelboom JW, Berger PB. et al. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective. Thromb Haemost 2011; 106: 572-584.
• 18 Huber K, Airaksinen KJ, Cuisset T. et al. Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: similarities and dissimilarities between North America and Europe. Throm Haemost 2011; 106: 569-571.
• 19 Nabauer M, Gerth A, Limbourg S. et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009; 11: 423-434
• 20 Ruiz-Nodar JM, Marín F, Hurtado JA. et al. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation: implications for bleeding risk and prognosis. J Am Coll Cardiol 2008; 51: 818-825.
• 21 Ruiz-Nodar JM, Marín F, Sánchez-Paya J. et al. Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. Eur Heart J 2009; 30: 932-939.
• 22 Ruiz-Nodar JM, Marín F, Lip GYH. Antithrombotic Management and Type of Stent in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. Rev Esp Cardiol 2013; 66: 12-16.
• 23 Connolly SJ, Eikelboom JW, Hirst J. et al; on behalf of the ACTIVE steering committee and investigators. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med 2011; 155: 579-586.